{"schema_version":"secwatch.filing_event.v1","accession":"0001641489-25-000058","form_type":"8-K","ticker":"VTVT","cik":"0001641489","company_name":"vTv Therapeutics Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.024650+00:00","generated_at":"2026-05-16T23:44:21.123612+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"vTv Therapeutics Q3 net loss $8.7M; Phase 3 CATT1 data expected H2 2026","bullets":["Net loss $8.7M ($1.08 per share) vs $4.8M loss ($0.88) in Q3 2024.","Cash $98.5M at Sept 30, 2025, up from $36.7M at Dec 31, 2024, after $80M private placement.","First patient randomized in Phase 3 CATT1 trial of cadisegliatin; topline data H2 2026.","U.S. patent allowed for crystalline salt forms of cadisegliatin; exclusivity through 2041.","R&D expenses $7.0M, more than double Q3 2024, due to cadisegliatin spend and milestone accrual."],"urls":{"canonical":"https://secwatch.observer/filing/0001641489-25-000058","json":"https://secwatch.observer/filing/0001641489-25-000058.json","markdown":"https://secwatch.observer/filing/0001641489-25-000058.md","text":"https://secwatch.observer/filing/0001641489-25-000058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641489/000164148925000058/0001641489-25-000058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641489/000164148925000058/vtvt-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:44:21.123612+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}